243 related articles for article (PubMed ID: 37401651)
1. State-of-the-art 2023 on gene therapy for phenylketonuria.
Martinez M; Harding CO; Schwank G; Thöny B
J Inherit Metab Dis; 2024 Jan; 47(1):80-92. PubMed ID: 37401651
[TBL] [Abstract][Full Text] [Related]
2. State-of-the-Art 2019 on Gene Therapy for Phenylketonuria.
Grisch-Chan HM; Schwank G; Harding CO; Thöny B
Hum Gene Ther; 2019 Oct; 30(10):1274-1283. PubMed ID: 31364419
[TBL] [Abstract][Full Text] [Related]
3. Administration-route and gender-independent long-term therapeutic correction of phenylketonuria (PKU) in a mouse model by recombinant adeno-associated virus 8 pseudotyped vector-mediated gene transfer.
Ding Z; Georgiev P; Thöny B
Gene Ther; 2006 Apr; 13(7):587-93. PubMed ID: 16319947
[TBL] [Abstract][Full Text] [Related]
4. Use of an adeno-associated virus serotype Anc80 to provide durable cure of phenylketonuria in a mouse model.
Kaiser RA; Weber ND; Trigueros-Motos L; Allen KL; Martinez M; Cao W; VanLith CJ; Hillin LG; Douar A; González-Aseguinolaza G; Aldabe R; Lillegard JB
J Inherit Metab Dis; 2021 Nov; 44(6):1369-1381. PubMed ID: 33896013
[TBL] [Abstract][Full Text] [Related]
5. Long-term correction of hyperphenylalaninemia by AAV-mediated gene transfer leads to behavioral recovery in phenylketonuria mice.
Mochizuki S; Mizukami H; Ogura T; Kure S; Ichinohe A; Kojima K; Matsubara Y; Kobayahi E; Okada T; Hoshika A; Ozawa K; Kume A
Gene Ther; 2004 Jul; 11(13):1081-6. PubMed ID: 15057263
[TBL] [Abstract][Full Text] [Related]
6. Long-term enzymatic and phenotypic correction in the phenylketonuria mouse model by adeno-associated virus vector-mediated gene transfer.
Oh HJ; Park ES; Kang S; Jo I; Jung SC
Pediatr Res; 2004 Aug; 56(2):278-84. PubMed ID: 15181195
[TBL] [Abstract][Full Text] [Related]
7. Treatment of a metabolic liver disease by in vivo genome base editing in adult mice.
Villiger L; Grisch-Chan HM; Lindsay H; Ringnalda F; Pogliano CB; Allegri G; Fingerhut R; Häberle J; Matos J; Robinson MD; Thöny B; Schwank G
Nat Med; 2018 Oct; 24(10):1519-1525. PubMed ID: 30297904
[TBL] [Abstract][Full Text] [Related]
8. A bone mineralization defect in the Pah
Dobrowolski SF; Tourkova IL; Robinson LJ; Secunda C; Spridik K; Blair HC
Mol Genet Metab; 2018 Nov; 125(3):193-199. PubMed ID: 30201326
[TBL] [Abstract][Full Text] [Related]
9. DNA methylation in the pathophysiology of hyperphenylalaninemia in the PAH(enu2) mouse model of phenylketonuria.
Dobrowolski SF; Lyons-Weiler J; Spridik K; Vockley J; Skvorak K; Biery A
Mol Genet Metab; 2016 Sep; 119(1-2):1-7. PubMed ID: 26822703
[TBL] [Abstract][Full Text] [Related]
10. Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2/8 vector-mediated gene therapy in murine phenylketonuria.
Harding CO; Gillingham MB; Hamman K; Clark H; Goebel-Daghighi E; Bird A; Koeberl DD
Gene Ther; 2006 Mar; 13(5):457-62. PubMed ID: 16319949
[TBL] [Abstract][Full Text] [Related]
11. A novel Pah-exon1 deleted murine model of phenylalanine hydroxylase (PAH) deficiency.
Richards DY; Winn SR; Dudley S; Fedorov L; Rimann N; Thöny B; Harding CO
Mol Genet Metab; 2020 Nov; 131(3):306-315. PubMed ID: 33051130
[TBL] [Abstract][Full Text] [Related]
12. Hepatocytes from wild-type or heterozygous donors are equally effective in achieving successful therapeutic liver repopulation in murine phenylketonuria (PKU).
Hamman KJ; Winn SR; Harding CO
Mol Genet Metab; 2011 Nov; 104(3):235-40. PubMed ID: 21917493
[TBL] [Abstract][Full Text] [Related]
13. Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector.
Yagi H; Ogura T; Mizukami H; Urabe M; Hamada H; Yoshikawa H; Ozawa K; Kume A
J Gene Med; 2011 Feb; 13(2):114-22. PubMed ID: 21322099
[TBL] [Abstract][Full Text] [Related]
14. Expression of phenylalanine hydroxylase (PAH) in erythrogenic bone marrow does not correct hyperphenylalaninemia in Pah(enu2) mice.
Harding CO; Neff M; Jones K; Wild K; Wolff JA
J Gene Med; 2003 Nov; 5(11):984-93. PubMed ID: 14601136
[TBL] [Abstract][Full Text] [Related]
15. Metabolic basis of sexual dimorphism in PKU mice after genome-targeted PAH gene therapy.
Chen L; Thung SN; Woo SL
Mol Ther; 2007 Jun; 15(6):1079-85. PubMed ID: 17406346
[TBL] [Abstract][Full Text] [Related]
16. Mutations in the phenylalanine hydroxylase gene: genetic determinants for the phenotypic variability of hyperphenylalaninemia.
Güttler F; Guldberg P
Acta Paediatr Suppl; 1994 Dec; 407():49-56. PubMed ID: 7766959
[TBL] [Abstract][Full Text] [Related]
17. Gene therapy for phenylketonuria.
Eisensmith RC; Woo SL
Acta Paediatr Suppl; 1994 Dec; 407():124-9. PubMed ID: 7766948
[TBL] [Abstract][Full Text] [Related]
18. Protective effect of recombinant adeno-associated virus 2/8-mediated gene therapy from the maternal hyperphenylalaninemia in offsprings of a mouse model of phenylketonuria.
Jung SC; Park JW; Oh HJ; Choi JO; Seo KI; Park ES; Park HY
J Korean Med Sci; 2008 Oct; 23(5):877-83. PubMed ID: 18955797
[TBL] [Abstract][Full Text] [Related]
19. Correction of murine PKU following AAV-mediated intramuscular expression of a complete phenylalanine hydroxylating system.
Ding Z; Harding CO; Rebuffat A; Elzaouk L; Wolff JA; Thöny B
Mol Ther; 2008 Apr; 16(4):673-81. PubMed ID: 18362925
[TBL] [Abstract][Full Text] [Related]
20. State-of-the-art 2003 on PKU gene therapy.
Ding Z; Harding CO; Thöny B
Mol Genet Metab; 2004 Jan; 81(1):3-8. PubMed ID: 14728985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
